Literature DB >> 3792407

Treatment of idiopathic West and Lennox-Gastaut syndromes by intravenous administration of human polyvalent immunoglobulins.

K van Rijckevorsel-Harmant, M Delire, M Rucquoy-Ponsar.   

Abstract

A total of 7 patients (3-21 years old) suffering from an intractable "primary" Lennox-Gastaut syndrome (LGS) were treated with i.v. high doses of polyvalent human immunoglobulins. Of these patients 6 improved following such treatment with a decrease in fits and an improvement in the EEG. Hypotheses about the contribution of the treatment and immunopathological factors in some cases of idiopathic LGS are discussed.

Entities:  

Mesh：

Year:  1986        PMID： 3792407     DOI： 10.1007/bf00454021

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Neurol Sci        ISSN： 0175-758X


  16 in total

1.  Immunogenetics of the Lennox-Gastaut syndrome: frequency of HL-A antigens and haplotypes in patients and first-degree relatives.

Authors:  E Smeraldi; R Scorza Smeraldi; C L Cazzullo; A Guareschi Cazzullo; G Fabio; R Canger
Journal:  Epilepsia       Date:  1975-12       Impact factor: 5.864

2.  Fc receptor dependency of antibody mediated feedback regulation: on the mechanism of inhibition.

Authors:  B Stockinger; E M Lemmel
Journal:  Cell Immunol       Date:  1978-10       Impact factor: 4.868

3.  S-sulfonation: a reversible chemical modification of human immunoglobulins permitting intravenous application. I. Physicochemical and binding properties of S-sulfonated and reconstituted IgG.

Authors:  P Gronski; T Hofstaetter; E J Kanzy; G Lüben; F R Seiler
Journal:  Vox Sang       Date:  1983       Impact factor: 2.144

4.  Immunoglobulins in epilepsy.

Authors:  M Bassanini; A Baez; J Sotelo
Journal:  J Neurol Sci       Date:  1982-11       Impact factor: 3.181

5.  High-dose intravenous IgG in adults with autoimmune thrombocytopenia.

Authors:  A C Newland; J G Treleaven; R M Minchinton; A H Waters
Journal:  Lancet       Date:  1983-01-15       Impact factor: 79.321

6.  IgA deficiency, epilepsy, and phenytoin treatment.

Authors:  J Seager; D L Jamison; J Wilson; A R Hayward; J F Soothill
Journal:  Lancet       Date:  1975-10-04       Impact factor: 79.321

7.  [Antibodies against nicotine-like acetylcholine receptors of central nervous system and muscles in epileptics with IgA deficiency].

Authors:  A Fontana; B W Fulpius; S Cuénoud
Journal:  Schweiz Med Wochenschr       Date:  1978-08-26

8.  HLA antigens in epileptic patients with drug-induced immunodeficiency.

Authors:  N E Gilhus; J A Aarli; E Thorsby
Journal:  Int J Immunopharmacol       Date:  1982

9.  Immunoglobulin concentrations in patients with a history of febrile convulsions prior to the development of epilepsy.

Authors:  N E Gilhus; J A Aarli
Journal:  Neuropediatrics       Date:  1981-11       Impact factor: 1.947

10.  Immunological aspects of epilepsy.

Authors:  J A Aarli; A Fontana
Journal:  Epilepsia       Date:  1980-10       Impact factor: 5.864
View more
  5 in total

1.  High-dose intravenous immunoglobulin treatment in cryptogenic West and Lennox-Gastaut syndrome; an add-on study.

Authors:  B G van Engelen; W O Renier; C M Weemaes; P F Strengers; P J Bernsen; S L Notermans
Journal:  Eur J Pediatr       Date:  1994-10       Impact factor: 3.183

Review 2.  Immunoglobulin therapy in neurologic diseases.

Authors:  P Berlit
Journal:  Klin Wochenschr       Date:  1989-10-02

3.  Treatment of Lennox-Gastaut syndrome: overview and recent findings.

Authors:  Kenou van Rijckevorsel
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

4.  Modulation of Immunity and the Inflammatory Response: A New Target for Treating Drug-resistant Epilepsy.

Authors:  Nian Yu; Hao Liu; Qing Di
Journal:  Curr Neuropharmacol       Date:  2013-01       Impact factor: 7.363

5.  Intravenous immunoglobulins for epilepsy.

Authors:  JinSong Geng; JianCheng Dong; Youping Li; HengJian Ni; Kui Jiang; Li Li Shi; GuoHua Wang
Journal:  Cochrane Database Syst Rev       Date:  2019-12-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.